INOVIQ LTD — Capital/Financing Update 2019

May 26, 2019

==> picture [155 x 46] intentionally omitted <==

BARD1 RECEIVES $520K R&D TAX INCENTIVE REFUND

Perth, Australia, 27 May 2019: BARD1 Life Sciences Limited (ASX:BD1) (BARD1 or the Company), a medical technology company developing non-invasive cancer diagnostics, is pleased to announce it has received a $520,518 Research and Development (R&D) Tax Incentive refund from the Australian Taxation Office (ATO) for the 2017/18 financial year.

The Australian Government’s R&D Tax Incentive Scheme supports eligible Australian companies to invest in R&D activities in Australia by providing cash rebates of 43.5% for eligible R&D expenditure. BARD1 received a “ R&D Tax Incentive – Advance and Overseas Finding Certificate” from AusIndustry on 18 February 2019 approving that its overseas R&D activities, in addition to its Australian activities, are eligible for the R&D Tax Incentive in the financial years 2017/18, 2018/19 and 2019/20. In 2017/18, BARD1 spent $1,196,594 on eligible R&D in Australia and overseas.

The funds will be used to progress the development and commercialisation of the BARD1 diagnostics pipeline.

• ENDS -

FOR MORE INFORMATION PLEASE CONTACT:

Peter Gunzburg Dr Leearne Hinch Chairman CEO E peter@bard1.com E leearne@bard1.com M +61 400 414 416

ABOUT BARD1 LIFE SCIENCES LTD

BARD1 Life Sciences Ltd (ASX:BD1) is an Australian medical technology company focused on developing and commercialising non-invasive diagnostic tests for early detection of cancer. BARD1 owns a proprietary tumour marker platform with potential diagnostic and therapeutic applications across multiple cancers. The pipeline includes BARD1 autoantibody tests in development for early detection of breast, ovarian and lung cancers. Additional diagnostic projects will be evaluated for other cancers. BARD1’s vision is to detect cancer early and save lives. For more information on BARD1, see www.bard1.com.

DISCLAIMER

This announcement contains “forward-looking statements” and “forward-looking information”, including statements and forecasts relating to the Company. Often, but not always, forward-looking information can be identified by the use of words such as “plans”, “expects”, “is expected”, “is expecting”, “budget”, “scheduled”, “estimates”, “forecasts”, “intends”, “anticipates”, or “believes”, or variations (including negative variations) of such words and phrases, or state that certain actions, events or results “may”, “could”, “would”, “might”, or “will” be taken, occur or be achieved. Such information is based on assumptions and judgements of management regarding future events and results. The purpose of forwardlooking information is to provide the audience with information about management’s expectations and plans. Readers are cautioned that forward-looking information involves known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of the Company and/or its subsidiaries to be materially different from any future results, performance or achievements expressed or implied by the forward-looking information.

BARD1 Life Sciences Limited (ABN 58 009 070 384) Registered Office | Suite B1, Tempo Building, 431 Roberts Road, Subiaco WA 6008, Australia P +618 9381 9550 | F +618 9388 7559 | E info@bard1.com | W www.bard1.com